Evaluation of degarelix in the management of prostate cancer

Cancer Management and Research

Volumn 2, Issue 1, 2010, Pages 39-52

  van Poppel, Hendrik ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Degarelix; GnRH receptor antagonist; GnRH receptor blocker; Prostate cancer

Indexed keywords

ABARELIX; CETRORELIX; DEGARELIX; ESTROGEN; GANIRELIX; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; LEUPRORELIN; MEGESTROL ACETATE; PHOSPHODIESTERASE V INHIBITOR; TAMOXIFEN;

ADVANCED CANCER; ALLERGIC REACTION; AREA UNDER THE CURVE; ARTHRALGIA; BACKACHE; CHILL; CLINICAL TRIAL; CONSTIPATION; DOSE CALCULATION; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERECTILE DYSFUNCTION; FATIGUE; GYNECOMASTIA; HOT FLUSH; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; INJECTION SITE REACTION; MASTALGIA; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PATIENT CARE; PLASMA CONCENTRATION-TIME CURVE; PROSTATE CANCER; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; URINARY TRACT INFECTION; WEIGHT GAIN;

EID: 77953449296     PISSN: None     EISSN: 11791322     Source Type: Journal    
DOI: 10.2147/cmr.s8841     Document Type: Review

References (58)

1. Huggins C, Stevens REJ, Hodges CV. Studies in prostatic cancer II. The effects of castration on advanced carcinoma of the prostate gland. Arch Surg. 1941;43:209-223.
2. FDA, US Food and Drug Administration: Cancer drug approval endpoints for prostate cancer 2009. Available from: http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/CancerDrugs/ucm094586.htm; Accessed Nov 16 2009.
3. Fleming MT, Morris MJ, Heller G, Scher HI. Post-therapy changes in PSA as an outcome measure in prostate cancer clinical trials. Nat Clin Pract Oncol. 2006;3(12):658-667.
4. Lilja H, Ulmert D, Vickers AJ. Prostate-specific antigen and prostate cancer: prediction, detection and monitoring. Nat Rev Cancer. 2008;8(4):268-278.
5. Huhtaniemi I, White R, McArdle CA, Persson BE. Will GnRH antagonists improve prostate cancer treatment? Trends Endocrinol Metab. 2009;20(1):43-50.
6. Rohl HF, Beuke HP. Effect of orchidectomy on serum concentrations of testosterone and dihydrotestosterone in patients with prostatic cancer. Scand J Urol Nephrol. 1992;26(1):11-14.
7. Heidenreich A, Bolla M, Joniau S, et al. Guidelines on Prostate Cancer. European Association of Urology, 2009. Available from: http://www.uroweb.org/professional-resources/guidelines/online; Accessed Oct 26 2009.
8. Conn PM, Crowley WF Jr. Gonadotropin-releasing hormone and its analogues. N Engl J Med. 1991;324(2):93-103.
9. Sasagawa I, Kubota Y, Nakada T, et al. Influence of luteinizing hormone releasing hormone analogues on serum levels of prostatic acid phosphatase and prostatic specific antigen in patients with metastatic carcinoma of the prostate. Int Urol Nephrol. 1998;30(6):745-753.
10. Tomera K, Gleason D, Gittelman M, et al. The gonadotropin-releasing hormone antagonist abarelix depot versus luteinizing hormone releasing hormone agonists leuprolide or goserelin: initial results of endocrinological and biochemical efficacies in patients with prostate cancer. J Urol. 2001;165(5):1585-1589.
11. Thompson IM, Zeidman EJ, Rodriguez FR. Sudden death due to disease flare with luteinizing hormone-releasing hormone agonist therapy for carcinoma of the prostate. J Urol. 1990;144(6):1479-1480.
12. Van Poppel H, Nilsson S. Testosterone surge: rationale for gonadotropin releasing hormone blockers? Urology. 2008;71(6):1001-1006.
13. Perlmutter MA, Lepor H. Androgen deprivation therapy in the treatment of advanced prostate cancer. Rev Urol. 2007;9 Suppl 1:S3-S8.
14. Kaisary AV, Iversen P, Tyrrell CJ, Carroll K, Morris T. Is there a role for antiandrogen monotherapy in patients with metastatic prostate cancer? Prostate Cancer Prostatic Dis. 2001;4(4):196-203.
15. Heidenreich H, Aus G, Abbou CC, et al. Guidelines on prostate cancer. European Association of Urology, 2007. Available from: http://www.uroweb.org/fileadmin/user_upload/Guidelines/07_Prostate_Cancer_2007.pdf; Accessed Aug 10 2009.
16. Sharifi R, Browneller R. Serum testosterone suppression and potential for agonistic stimulation during chronic treatment with monthly and 3-month depot formulations of leuprolide acetate for advanced prostate cancer. J Urol. 2002;168(3):1001-1004.
17. Zinner NR, Bidair M, Centeno A, Tomera K. Similar frequency of testosterone surge after repeat injections of goserelin (Zoladex) 3.6 mg and 10.8 mg: results of a randomized open-label trial. Urology. 2004;64(6):1177-1181.
18. Morote J, Orsola A, Planas J, et al. Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy. J Urol. 2007;178(4 Pt 1):1290-1295.
19. Perachino M, Cavalli V, Bravi F. Testosterone levels in patients with metastatic prostate cancer treated with luteinizing hormone-releasing hormone therapy: prognostic significance? BJU Int. 2009. Aug 28 [Epub ahead of print].
20. Jockenhovel F, Bhasin S, Steiner BS, Rivier JE, Vale WW, Swerdloff RS. Hormonal effects of single gonadotropin-releasing hormone antagonist doses in men. J Clin Endocrinol Metab. 1988;66(5):1065-1070.
21. Salameh W, Bhasin S, Steiner B, McAdams LA, Peterson M, Swerdloff R. Marked suppression of gonadotropins and testosterone by an antagonist analog of gonadotropin-releasing hormone in men. Fertil Steril. 1991;55(1):156-164.
22. Bagatell CJ, Conn PM, Bremner WJ. Single-dose administration of the gonadotropin-releasing hormone antagonist, Nal-Lys (antide) to healthy men. Fertil Steril. 1993;60(4):680-685.
23. Bagatell CJ, Rivier JE, Bremner WJ. Dose effects of the gonadotropin-releasing hormone antagonist, Nal-Glu, combined with testosterone enanthate on gonadotropin levels in normal men. Fertil Steril. 1995; 64(1):139-145.
24. Klingmuller D, Schepke M, Enzweiler C, Bidlingmaier F. Hormonal responses to the new potent GnRH antagonist Cetrorelix. Acta Endocrinol (Copenh). 1993;128(1):15-18.
25. Broqua P, Riviere PJ, Conn PM, Rivier JE, Aubert ML, Junien JL. Pharmacological profile of a new, potent, and long-acting gonadotropin releasing hormone antagonist: degarelix. J Pharmacol Exp Ther. 2002; 301(1):95-102.
26. Debruyne F, Bhat G, Garnick MB. Abarelix for injectable suspension: first-in-class gonadotropin-releasing hormone antagonist for prostate cancer. Future Oncol. 2006;2(6):677-696.
27. PR Newswire. FDA approves Ferring Pharmaceuticals' Degarelix (generic name) for the treatment of advanced prostate cancer. PR Newswire, Europe Ltd, 2008. Available from: http://www.prnewswire.co.uk/cgi/news/release?id=245656; Accessed Mar 2 2009.
28. Jiang G, Stalewski J, Galyean R, et al. GnRH antagonists: a new generation of long acting analogues incorporating p-ureido-phenylalanines at positions 5 and 6. J Med Chem. 2001;44(3):453-467.
29. European Medicines Agency. Assessment report for Firmagon (Doc. Ref: EMEA/CHMP/635761/2008). Available from: http://www.emea.europa.eu/humandocs/PDFs/EPAR/firmagon/H-986-en6.pdf; Accessed Apr 28 2009.
30. Koechling W. Effect of various GnRH antagonists on histamine release from human skin. Poster presented at the 8th International Symposium on GnRH Analogues in Cancer and Human Reproduction; 2005 Nov 2; Salzburg, Austria.
31. Agerso H, Koechling W, Knutsson M, Hjortkjaer R, Karlsson MO. The dosing solution influence on the pharmacokinetics of degarelix, a new GnRH antagonist, after s.c. administration to beagle dogs. Eur J Pharm Sci. 2003;20(3):335-340.
32. Doehn C, Sommerauer M, Jocham D. Drug evaluation: Degarelix a potential new therapy for prostate cancer. IDrugs. 2006;9(8):565-572.
33. Degarelix US prescribing information. 2008. Available from: http://www.fda.gov/cder/foi/label/2008/022201lbl.pdf; Accessed Apr 28 2009.
34. Balchen T, Agerso H, Olesen TK, Jensen JK, Senderovitz T. Pharmacokinetics, pharmacodynamics, and safety of a novel fast-acting gonadotropin releasing hormone receptor blocker, degarelix, in healthy men. Poster presented at the 8th International Symposium on GnRH Analogues in Cancer and Human Reproduction; 2005 Nov 2; Salzburg, Austria.
35. Iversen P, Van Poppel H, Tammela T, et al. Determining the optimal initiation and maintenance dose of degarelix for hormone therapy of prostate cancer patients. Poster presented at the 28th Congress of the Société Internationale d'Urologie; 2006 Nov 12-15; Cape Town, South Africa.
36. Van Poppel H, Tombal B, de la Rosette JJ, Persson BE, Jensen JK, Kold OT. Degarelix: a novel gonadotropin-releasing hormone (GnRH) receptor blocker results from a 1-yr, multicentre, randomised, phase II dosage-finding study in the treatment of prostate cancer. Eur Urol. 2008;54(4):805-813.
37. Gittelman M, Pommerville PJ, Persson BE, Jensen JK, Olesen TK. A 1-year, open label, randomized phase II dose finding study of degarelix for the treatment of prostate cancer in North America. J Urol. 2008;180(5):1986-1992.
38. Klotz L, Boccon-Gibod L, Shore ND, et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel group phase III study in patients with prostate cancer. BJU Int. 2008; 102(11):1531-1538.
39. Tombal B, Miller K, Boccon-Gibod L, et al. Additional analysis of the secondary endpoint of biochemical recurrence rate in a phase 3 trial (CS21) comparing degarelix 80 mg versus leuprolide in patients with prostate cancer segmented by baseline characteristics. Eur Urol. 2009. Nov 20 [Epub ahead of print].
40. Jung K, Lein M, Stephan C, et al. Comparison of 10 serum bone turnover markers in prostate carcinoma patients with bone metastatic spread: diagnostic and prognostic implications. Int J Cancer. 2004;111(5):783-791.
41. Damber JE, Tammela T, Abrahamsson PA, et al. Comparing testosterone and PSA for different baseline testosterone concentrations during initiation of degarelix and leuprolide treatment [abstract]. Eur Urol. 2009;Suppl 8:130.
42. Schröder FH, Tombal B, Miller K, et al. Changes in alkaline phosphatase levels in patients with prostate cancer receiving degarelix or leuprolide: results from a 12-month, comparative, phase III study. BJU Int. 2009. Nov 13 [Epub ahead of print].
43. Iversen P, Jensen JK, Olesen TK, Persson BE. Phase III trial of degarelix vs leuprolide: comparing safety and tolerability. Presented at the World Congress on Controversies in Urology; 2009 Feb 5; Lisbon, Portugal. Abstract 618148.
44. Cassileth BR, Soloway MS, Vogelzang NJ, et al. Quality of life and psychosocial status in stage D prostate cancer. Zoladex Prostate Cancer Study Group. Qual Life Res. 1992;1(5):323-329.
45. Gomella LG. Contemporary use of hormonal therapy in prostate cancer: managing complications and addressing quality-of-life issues. BJU Int. 2007;99 Suppl 1:25-29.
46. Michaelson MD, Cotter SE, Gargollo PC, Zietman AL, Dahl DM, Smith MR. Management of complications of prostate cancer treatment. CA Cancer J Clin. 2008;58(4):196-213.
47. Gleave M, Klotz L, Taneja SS. The continued debate: intermittent vs continuous hormonal ablation for metastatic prostate cancer. Urol Oncol. 2009;27(1):81-86.
48. Gerber GS, Zagaja GP, Ray PS, Rukstalis DB. Transdermal estrogen in the treatment of hot flushes in men with prostate cancer. Urology. 2000;55(1):97-101.
49. Loprinzi CL, Michalak JC, Quella SK, et al. Megestrol acetate for the prevention of hot flashes. N Engl J Med. 1994;331(6):347-352.
50. Loprinzi CL, Pisansky TM, Fonseca R, et al. Pilot evaluation of venla faxine hydrochloride for the therapy of hot flashes in cancer survivors. J Clin Oncol. 1998;16(7):2377-2381.
51. Loprinzi CL, Barton DL, Carpenter LA, et al. Pilot evaluation of paroxetine for treating hot flashes in men. Mayo Clin Proc. 2004;79(10): 1247-1251.
52. Widmark A, Fossa SD, Lundmo P, et al. Does prophylactic breast irradiation prevent antiandrogen-induced gynecomastia? Evaluation of 253 patients in the randomized Scandinavian trial SPCG-7/SFUO-3. Urology. 2003;61(1):145-151.
53. Saltzstein D, Sieber P, Morris T, Gallo J. Prevention and management of bicalutamide-induced gynecomastia and breast pain: randomized endocrinologic and clinical studies with tamoxifen and anastrozole. Prostate Cancer Prostatic Dis. 2005;8(1):75-83.
54. Lein M, Wirth M, Miller K, et al. Serial markers of bone turnover in men with metastatic prostate cancer treated with zoledronic acid for detection of bone metastases progression. Eur Urol. 2007;52(5): 1381-1387.
55. Smith MR, McGovern FJ, Zietman AL, et al. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med. 2001;345(13):948-955.
56. Ryan CW, Huo D, Bylow K, et al. Suppression of bone density loss and bone turnover in patients with hormone-sensitive prostate cancer and receiving zoledronic acid. BJU Int. 2007;100(1):70-75.
57. Lebret T, Bouregba A. Roles of the urologist and nurse from the perspective of patients with prostate cancer receiving luteinizing hormone-releasing hormone analogue therapy. BJU Int. 2008;102(10): 1419-1424.
58. Anderson J. Degarelix: a novel gonadotropin-releasing hormone blocker for the treatment of prostate cancer. Future Oncol. 2009;5(4): 433-443.